Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03751488 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

A Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by Luye Pharma Group.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
2
Study locations

NCT03751488: Completed Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by Luye Pharma Group.

NCT03751488 is a Phase 1 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Luye Pharma Group. The registered enrollment target is 48 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03751488, a Phase 1 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Luye Pharma Group.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
2
Study locations

Study Summary

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

Primary Outcome

Area under the concentration

Conditions Studied

Schizophrenia Schizoaffective Disorder

Interventions

  • DRUG LY03010
  • DRUG Invega Sustenna 156 MG in 1 ML Prefilled Syringe

Study Locations (2)

California

  • Collaborative Neuroscience Network LLC - Garden Grove

New Jersey

  • Hassman Research Institute - Berlin

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2018-12-12
Est. Completion 2019-07-24
Phase Phase 1
Luye Pharma Group

22 total trials

What the finished NCT03751488 record still lists

NCT03751488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower).

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which LY03010 is the first listed.

NCT03751488 reports a single indexed study location in California, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03751488 about?

NCT03751488 is a clinical study titled "A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients". This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

What is the current status of trial NCT03751488?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-12-12. Estimated completion is 2019-07-24.

What conditions does trial NCT03751488 study?

This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.

What interventions are being tested in trial NCT03751488?

The interventions under investigation include: LY03010 (DRUG), Invega Sustenna 156 MG in 1 ML Prefilled Syringe (DRUG).

Who is sponsoring clinical trial NCT03751488?

This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03751488 being conducted?

This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03751488's enrollment target sits among peer trials

48 218th of 315 higher than 94 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03751488, the US trial registry maintained by the National Library of Medicine. NCT03751488 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.